{"SPADE_UN_13533": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_13533", "Peptide Name": "LCB3", "Source": "Synthetic construct", "Family": "Not found", "Gene": "Not found", "Sequence": "NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS", "Sequence Length": 64, "UniProt Entry": "No entry found", "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Antiviral(SARS-CoV-2)"], "Target Organism": "[Ref.32907861]Virus:SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=48.1 pM).", "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry", "Cytotoxicity": "No cytotoxicity information found in the reference(s) presented", "Binding Target": "Not found", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C346H556N90O106S2", "Mass": 7736.79, "PI": 4.94, "Net Charge": -3, "Hydrophobicity": -0.66, "Half Life": "Mammalian:1.4 hourYeast:3 minE.coli:>10 hour", "Mechanism of action": "The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding.", "Literature": [{"Title": "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.", "Pubmed ID": "32907861", "Reference": "Science. 2020 Oct 23;370(6515)426-431.", "Author": "Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=32907861"}], "Frequent Amino Acids": "LEK", "Absent Amino Acids": "CGOPUW", "Basic Residues": 13, "Acidic Residues": 16, "Hydrophobic Residues": 28, "Polar Residues": 30, "Positive Residues": 13, "Negative Residues": 16, "Similar Sequences": []}}}